HC Wainwright reissued their buy rating on shares of Sensei Biotherapeutics (NASDAQ:SNSE – Free Report) in a report released on Friday morning, Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.
Separately, Stephens reissued an overweight rating and set a $5.00 price target on shares of Sensei Biotherapeutics in a research report on Friday.
View Our Latest Stock Analysis on SNSE
Sensei Biotherapeutics Stock Performance
Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). As a group, sell-side analysts anticipate that Sensei Biotherapeutics will post -1.07 EPS for the current fiscal year.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 5/20 – 5/24
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- CD Calculator: Certificate of Deposit Calculator
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.